



CryoLife Declares a Dividend of Approximately \$0.75 on Its Convertible Preferred Stock

March 13, 2006

ATLANTA, March 13 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials and biosurgical device company, announced today that the Company declared a dividend of approximately \$0.75 per share on its 6% convertible preferred stock payable on April 3, 2006, to shareholders of record at the close of business on March 23, 2006.

About CryoLife

Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiovascular and vascular surgeries throughout the United States and Canada. The Company's BioGlue(R) Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels, CE marked in the European Community and approved in Canada for use in soft tissue repair, and approved in Australia for use in vascular and pulmonary sealing and repair. The Company also manufactures the SG Model #100 vascular graft, which is CE marked for distribution within the European Community.

For additional information about the Company, visit CryoLife's Web site: <http://www.cryolife.com>

Media Contacts:

D. Ashley Lee

Executive Vice President, Chief Financial
Officer and Chief Operating Officer
Phone: 770-419-3355

Katie Brazel

Fleishman Hillard
Phone: 404-739-0150

SOURCE CryoLife, Inc.

CONTACT: D. Ashley Lee, Executive Vice President, Chief Financial Officer and Chief Operating Officer of CryoLife, Inc., +1-770-419-3355; or Katie Brazel of Fleishman Hillard, +1-404-739-0150